iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway

Significance CD24+CD133+ liver cancer stem cells (LCSCs) express higher levels of the inducible nitric oxide synthase (iNOS) and possess self-renewal and tumor growth properties. iNOS is associated with more aggressive hepatocellular carcinoma (HCC), leading to the upregulation of Notch1 signaling. The activation of Notch1 by iNOS/NO is dependent on cGMP/PKG-mediated activation of TACE and upregulation of iRhom-2. The expression of iNOS, CD24, and CD133 correlates with the expression of activated TACE and Notch signaling in more aggressive human HCC. These findings have implications for understanding how LCSCs are regulated in the setting of chronic inflammation, where signals to upregulate iNOS are often present. Targeting iNOS could have therapeutic benefit in HCC. The inducible nitric oxide synthase (iNOS) is associated with more aggressive solid tumors, including hepatocellular carcinoma (HCC). Notch signaling in cancer stem cells promotes cancer progression and requires Notch cleavage by ADAM (a disintegrin and metalloprotease) proteases. We hypothesized that iNOS/NO promotes Notch1 activation through TACE/ADAM17 activation in liver cancer stem cells (LCSCs), leading to a more aggressive cancer phenotype. Expression of the stem cell markers CD24 and CD133 in the tumors of patients with HCC was associated with greater iNOS expression and worse outcomes. The expression of iNOS in CD24+CD133+ LCSCs, but not CD24−CD133− LCSCs, promoted Notch1 signaling and stemness characteristics in vitro and in vivo, as well as accelerating HCC initiation and tumor formation in the mouse xenograft tumor model. iNOS/NO led to Notch1 signaling through a pathway involving the soluble guanylyl cyclase/cGMP/PKG-dependent activation of TACE/ADAM17 and up-regulation of iRhom2 in LCSCs. In patients with HCC, higher TACE/ADAM17 expression and Notch1 activation correlated with poor prognosis. These findings link iNOS to Notch1 signaling in CD24+CD133+ LCSCs through the activation of TACE/ADAM17 and identify a mechanism for how iNOS contributes to progression of CD24+CD133+ HCC.

[1]  Jenny C. Chang,et al.  NO and COX2: Dual targeting for aggressive cancers , 2017, Proceedings of the National Academy of Sciences.

[2]  J. Weiss,et al.  Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer , 2017, Proceedings of the National Academy of Sciences.

[3]  D. Geller,et al.  Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells , 2015, Oncotarget.

[4]  S. Ambs,et al.  The Oncogenic Properties Of The Redox Inflammatory Protein Inducible Nitric Oxide Synthase In ER(-) Breast Cancer. , 2015, Redox biology.

[5]  Hong Zhao,et al.  Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.

[6]  P. Dempsey,et al.  ADAM10 regulates Notch function in intestinal stem cells of mice. , 2014, Gastroenterology.

[7]  Qian Sun,et al.  Notch1 promotes hepatitis B virus X protein-induced hepatocarcinogenesis via Wnt/β-catenin pathway. , 2014, International journal of oncology.

[8]  D. Raha,et al.  The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.

[9]  D. Geller,et al.  Nitric oxide production upregulates Wnt/β-catenin signaling by inhibiting Dickkopf-1. , 2013, Cancer research.

[10]  Jane J. Sohn,et al.  Macrophages, Nitric Oxide and microRNAs Are Associated with DNA Damage Response Pathway and Senescence in Inflammatory Bowel Disease , 2012, PloS one.

[11]  T. Billiar,et al.  A Role for cGMP in Inducible Nitric-oxide Synthase (iNOS)-induced Tumor Necrosis Factor (TNF) α-converting Enzyme (TACE/ADAM17) Activation, Translocation, and TNF Receptor 1 (TNFR1) Shedding in Hepatocytes* , 2012, The Journal of Biological Chemistry.

[12]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[13]  M. Freeman,et al.  Tumor Necrosis Factor Signaling Requires iRhom2 to Promote Trafficking and Activation of TACE , 2012, Science.

[14]  C. Blobel,et al.  iRhom2 Regulation of TACE Controls TNF-Mediated Protection Against Listeria and Responses to LPS , 2012, Science.

[15]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[16]  J. Stamler,et al.  Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2 , 2011, Cell.

[17]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[18]  A. Maitra,et al.  A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors , 2011, Cancer biology & therapy.

[19]  I. Ng,et al.  miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. , 2010, Cell stem cell.

[20]  Manuel Hidalgo,et al.  Tumor-initiating cells are rare in many human tumors. , 2010, Cell stem cell.

[21]  C. Brennan,et al.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.

[22]  Guido Nikkhah,et al.  NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.

[23]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[24]  K. Engels,et al.  Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin , 2009, International journal of cancer.

[25]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[26]  S. Loibl,et al.  NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. , 2008, Cancer research.

[27]  Lei Xu,et al.  Perivascular nitric oxide gradients normalize tumor vasculature , 2008, Nature Medicine.

[28]  R. Adams,et al.  Regulation of vascular morphogenesis by Notch signaling. , 2007, Genes & development.

[29]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[30]  Daniel J. Hoeppner,et al.  Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.

[31]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[32]  M. Djamgoz,et al.  Nitric oxide and metastatic cell behaviour , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[33]  G. Gores,et al.  Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. , 2005, Gastroenterology.

[34]  D. L. Wilson,et al.  IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells , 2003, Leukemia.

[35]  E. Dı́az-Rodrı́guez,et al.  Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. , 2002, Molecular biology of the cell.

[36]  Ding-I Yang,et al.  NO‐Mediated Chemoresistance in C6 Glioma Cells , 2002, Annals of the New York Academy of Sciences.

[37]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[38]  P K Lala,et al.  Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.

[39]  C. Harris,et al.  Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A Cumano,et al.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.

[41]  S. Tannenbaum,et al.  DNA damage in deoxynucleosides and oligonucleotides treated with peroxynitrite. , 1999, Chemical research in toxicology.

[42]  Y. Vodovotz,et al.  The role of nitric oxide chemistry in cancer treatment. , 1998, Biochemistry. Biokhimiia.

[43]  S. Kaur,et al.  Cells , 2019, Tissue Engineering in Oral and Maxillofacial Surgery.

[44]  Jing Luo,et al.  The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. , 2016, OncoTarget.

[45]  J. Weiss,et al.  NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression , 2013, International journal of cancer.